Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| MacroGenics Inc. | Lorigerlimab (MGD019) - (LORIKEET) | Prostate cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Madrigal Pharmaceuticals Inc. | Resmetirom (MGL-3196) - (MAESTRO-NAFLD-1) | Non-Alcoholic Fatty Liver Disease | Phase 3 | Data Released | Oral | Gastroenterology |
| Madrigal Pharmaceuticals Inc. | Resmetirom (MGL-3196) - (MAESTRO-NAFLD-1) | Non-Alcoholic Fatty Liver Disease | Phase 3 | Data Released | Oral | Gastroenterology |
| Madrigal Pharmaceuticals Inc. | Resmetirom - (MAESTRO-NASH Outcomes) | Nonalcoholic Steatohepatitis (NASH) | Phase 3 | Ongoing | Oral | Gastroenterology |
| Madrigal Pharmaceuticals Inc. | Ervogastat (PF-06865571) and clesacostat (PF-05221304) | Metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis | Phase 2 | Oral | Gastroenterology | |
| Madrigal Pharmaceuticals Inc. | MGL-3196 | Heterozygous familial hypercholesterolemia (HeFH) | Phase 2 | Trial Discontinued | oral | Cardiology |
| MAIA Biotechnology Inc. | Ateganosine (THIO-104) | Non-small Cell Lung Cancer | Phase 3 | Enrollment Initiation | Oral | Oncology |
| MAIA Biotechnology Inc. | Ateganosine (THIO-103) - (basket trial) | Solid tumors | Phase 2/3 | Trial Planned | Oral | Oncology |
